Societal Economic Burden of Antibiotic Resistance in Uganda: A Cost of Illness Study [0.03%]
乌干达抗生素抗药性的社会经济负担：一种疾病负担研究
Elly Nuwamanya,Jonathan Mayito,Stephen Okoboi et al.
Elly Nuwamanya et al.
Background: Antibiotic resistance (ABR), largely owing to inappropriate prescriptions and misuse of antibiotics, threatens the effectiveness of current and future antibiotic treatments, resulting in prolonged hospitalizat...
Global Assessment of Health Utilities Associated with Pneumococcal Disease in Adults: Targeted Literature Reviews [0.03%]
成人肺炎球菌性疾病健康效用全球评估：目标文献回顾
Min Huang,Jipan Xie,Hela Romdhani et al.
Min Huang et al.
Background: Pneumococcal disease can significantly reduce quality of life (QoL). Health utilities are commonly used to assess QoL burden and calculate quality-adjusted life years (QALYs), which are critical inputs in cost...
Impact of Inhibitor Development on the Cost Effectiveness of Prophylactic Treatment with Recombinant Factor VIII in Previously Untreated Patients with Severe Hemophilia A [0.03%]
抑制剂生成对严重甲型血友病患者使用重组VIII因子进行预防性治疗的成本效益的影响分析
Li Yang,Jie Peng,Congling Gu et al.
Li Yang et al.
Background/objectives: Inhibitor development against recombinant factor VIII (rFVIII) is a significant complication in the prophylactic treatment of severe hemophilia A. The economic impact of varying inhibitor risks amon...
Model-Based Economic Analyses of Haemophilia from a Societal Perspective: A Scoping Review [0.03%]
基于模型的经济学分析：血友病社会视角下的综述研究
Amr A El-Sayed,Nancy S Bolous
Amr A El-Sayed
Introduction: Haemophilia imposes substantial lifelong humanistic and economic burdens, necessitating economic evaluations that adopt a societal perspective and comprehensively capture all relevant costs. Given the rarity...
Estimation of Health Utility Values for Eosinophilic Granulomatosis With Polyangiitis [0.03%]
估计肉芽肿性多血管炎的健康效用值
Bhovina Buguth,Jacqui Bernarde,Daniel Aggio et al.
Bhovina Buguth et al.
Background: Eosinophilic granulomatosis with polyangiitis (EGPA) is a rare autoimmune disease, characterised by inflammation of small- to medium-sized blood vessels, however, it remains poorly described in the literature....
Cost-Effectiveness Analysis of Etrasimod Compared With Biologic Therapies for the Treatment of Patients with Moderately-to-Severely Active Ulcerative Colitis in Spain [0.03%]
西班牙对中至重度活动性溃疡性结肠炎患者使用艾替洛尔与生物制剂治疗的成本效益分析
Iago Rodríguez-Lago,Fernando Muñoz Núñez,Alfredo J Lucendo et al.
Iago Rodríguez-Lago et al.
Background: Etrasimod (2 mg orally, once daily) is a novel advanced therapy (AT) for patients aged 16 years and older, with moderately-to-severely active ulcerative colitis (UC). This cost-effectiveness analysis compared ...
Cost of Chronic Heart Failure Among Adult Europeans-A Systematic Literature Review [0.03%]
欧洲成人慢性心力衰竭的经济负担——系统评价
Alexandra Mincă,Claudiu C Popescu,Dragoş I Mincă et al.
Alexandra Mincă et al.
Background: Chronic heart failure (CHF) imposes a substantial and growing burden on healthcare systems. While individual studies have evaluated the cost of CHF, variability in reporting standards and regional data gaps li...
Cost-Effectiveness Analysis of Abrocitinib Compared with Dupilumab for Adolescents With Severe Atopic Dermatitis in Spain [0.03%]
与度普利尤单抗相比，阿布昔替尼治疗西班牙中重度特应性皮炎青少年的成本效益分析
Rosa María Romero Jiménez,Pedro Herranz Pinto,Minia Campos Domínguez et al.
Rosa María Romero Jiménez et al.
Health Utility Decrement of Injection Treatment-Related Attributes Using Time Trade-Off Among Type 2 Diabetes Patients: A Vignette-Based Study [0.03%]
基于情节的2型糖尿病患者注射治疗相关属性时间贸易-off研究健康效用减量
Xinran Liu,Chang Luo,Shitong Xie et al.
Xinran Liu et al.
Objectives: To identify health utility decrements of injection treatment-related attributes among patients with type 2 diabetes mellitus (T2DM) in China. ...